Integrating Public Health Concerns into Patent Legislation in Developing Countries
(2000; 140 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoTHE SOUTH CENTRE
Ver el documentoFOREWORD
Ver el documentoACKNOWLEDGEMENTS
Ver el documentoGLOSSARY*
Abrir esta carpeta y ver su contenidoI. INTRODUCTION
Abrir esta carpeta y ver su contenidoII. PATENTABLE SUBJECT MATTER
Abrir esta carpeta y ver su contenidoIII. SCOPE OF CLAIMS
Abrir esta carpeta y ver su contenidoIV. PATENTABILITY REQUIREMENTS
Abrir esta carpeta y ver su contenidoV. SPECIAL CASES IN PHARMACEUTICALS
Abrir esta carpeta y ver su contenidoVI. DISCLOSURE
Cerrar esta carpetaVII. EXCEPTIONS TO EXCLUSIVE RIGHTS
Cerrar esta carpetaVII.1 Experimental Use
Ver el documentoVII.1.1 Options - Experimental Use
Abrir esta carpeta y ver su contenidoVII.2 Early Working
Abrir esta carpeta y ver su contenidoVII.3 Parallel Imports
Abrir esta carpeta y ver su contenidoVII.4 Individual Prescriptions
Abrir esta carpeta y ver su contenidoVIII. EXAMINATION AND OBSERVATION PROCEDURES
Abrir esta carpeta y ver su contenidoIX. CLAIMS INTERPRETATION
Abrir esta carpeta y ver su contenidoX. COMPULSORY LICENSING
Ver el documentoXI. FINAL REMARKS
Ver el documentoREFERENCES
Ver el documentoBACK COVER
 

VII.1 Experimental Use

A basic objective of the patent law is to promote innovation. Overly broad patent rights may harm innovation, however120. One mechanism to address this problem is through a patent exception relating to research and experimentation, permitting use of the invention without compensation to the owner for such purposes. An experimental use exception may foster technological progress based on “inventing around” or improving a protected invention, as well as permit evaluation of an invention in order to request a license, or for other legitimate purposes, such as to test whether the patent is valid121.

120 See, e.g., Mazzoleni and Nelson, 1998.

121 See, e.g., Eisenberg, 1989; Gilat, 1995.

While the experimentation exception is rather narrow in the United States122, many countries (notably in Europe) explicitly authorize experimentation on an invention without the consent of the patent owner, for scientific as well as commercial purposes123.

122 See, e.g., Wegner, 1994, p. 267

123 See, e.g., Cornish, 1998, p. 736.

An experimental use exception, including one for certain commercial purposes, seem to fall clearly within the category of admitted exceptions under Article 30 of the TRIPs Agreement. However, actual application of such an exception that leads to rival products not significantly different from the patented product may be deemed an infringement under the “doctrine of equivalents” in some countries’ national case law (see section 9 below).

Ir a la sección anterior
Ir a la siguiente sección
 
 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019